Imaging in renal cell carcinoma

Hematology/Oncology Clinics of North America

Volumn 25, Issue 4, 2011, Pages 687-715

  Krajewski, Katherine M ^a,b   Giardino, Angela A ^a,b   Zukotynski, Katherine ^a,b   Van den Abbeele, Annick D ^a,b   Pedrosa, Ivan ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Diagnosis; Imaging; Management; Renal cell carcinoma

Indexed keywords

EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANGIOMYOLIPOMA; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL EVALUATION; CRYOABLATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR THROMBUS; VASCULARIZATION;

CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; HUMANS; KIDNEY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79960344085     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.04.005     Document Type: Review

References (116)

1. Choudhary S., Sudarshan S., Choyke P.L., et al. Renal cell carcinoma: recent advances in genetics and imaging. Semin Ultrasound CT MR 2009, 30(4):315-325.
2. Vikram R., Ng C.S., Tamboli P., et al. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 2009, 29:741-754.
3. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. JAMA 1999, 281:1628-1631.
4. Bosniak M.A. The current radiological approach to renal cysts. Radiology 1986, 158:1-10.
5. Bosniak M.A. The small (less than or equal to 3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology 1991, 179:307-317.
6. Israel G.M., Hindman N., Bosniak M.A. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology 2004, 231:365-371.
7. Habboub H.K., Abu-Yousef H.M., Williams R.D., et al. Accuracy of color Doppler sonography in assessing venous thrombus extension in renal cell carcinoma. AJR Am J Roentgenol 1997, 168(1):267-271.
8. Chow L.C., Kwan S.W., Olcott E.W., et al. Split-bolus MDCT urography with synchronous nephrographic and excretory phase enhancement. AJR 2007, 189(2):314-322.
9. Bosniak M.A., Megibow A.J., Hulnick D.H., et al. CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat. AJR 1988, 151(3):497-501.
10. Israel G.M., Hindman N., Hecht E., et al. The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas. AJR 2005, 184:1868-1872.
11. Zhang J., Lefkowicz R.A., Bach A. Imaging of kidney cancer. Radiol Clin North Am 2007, 45(1):119-147.
12. Adey G.S., Pedrosa I., Rofsky N.R., et al. Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms. Urology 2008, 71:47-51.
13. Semelka R.C., Shoenut J.P., Magro C.M., et al. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993, 3(4):597-602.
14. Lawrentschuk N., Davis I.D., Bolton D.M., et al. Functional imaging of renal cell carcinoma. Nat Rev Urol 2010, 7:258-266.
15. Lawrentschuk N., Bolton D.M., Davis I.D., et al. Renal cell cancer and positron emission tomography- an evolving diagnostic and therapeutic relationship. Current Medical Imaging Reviews 2007, 3:17-26.
16. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 2010, 5:95-112.
17. Avril N., Dambha F., Murray I., et al. The clinical advances of fluorine-2-d-deoxyglucose - positron emission tomography/computed tomography in urological cancers. Int J Urol 2010, 17(6):501-511.
18. Aide N., Cappele O., Bottet P., et al. Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 2003, 30(9):1236-1245.
19. Kang D.E., White J.R., Zuger J.H., et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004, 171(5):1806-1809.
20. Majhail N.S., Urbain J., Albani J.M., et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003, 21(21):3995-4000.
21. Revheim M.E., Winge-Main A.K., Hagen G., et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 2011, 23(5):339-343.
22. Minamimoto R., Nakaigawa N., Tateishi U., et al. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med 2010, 35:918-923.
23. Vercellino L., Bousquet G., Baillet G., et al. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 2009, 24(1):137-144.
24. Powles T., Chowdhury S., Avril N., et al. Sequential FDG-PET/CT as a surrogate marker of response to sunitinib in metastatic clear cell renal cancer. J Clin Oncol 2011, 29(Suppl 7). [abstract: 301].
25. Namura K., Minamimoto R., Yao M., et al. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 2010, 10:667-673.
26. Park J.W., Jo M.K., Lee H.M. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 2009, 103(5):615-619.
27. Kaelin W.G. Kidney cancer: now available in a new flavor. Cancer Cell 2008, 14(6):423-424.
28. Zhang J., Lefkowitz R.A., Ishill N.M., et al. Solid renal cortical tumors: differentiation with CT. Radiology 2007, 244(2):494-504.
29. Sun M.R., Pedrosa I. Magnetic resonance imaging of renal masses. Semin Ultrasound CT MR 2009, 30:326-351.
30. Sun M.R., Ngo L., Genega E.M., et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes - correlation with pathologic findings. Radiology 2009, 250(3):793-802.
31. Yamashita Y., Watanabe O., Miyazaki T., et al. Cystic renal cell carcinoma. Acta Radiol 1994, 35(1):19-24.
32. Pedrosa I., Chou M.T., Ngo L., et al. MR classification of renal masses with pathologic correlation. Eur Radiol 2008, 18:365-375.
33. Roy C., Sauer B., Lindner V., et al. Imaging of papillary renal neoplasms: potential application for characterization of small renal masses. Eur Radiol 2007, 17:193-200.
34. Yoshimitsu K., Kakihara D., Irie H., et al. Papillary renal carcinoma: diagnostic approach by chemical shift gradient-echo and echo-planar MR imaging. J Magn Reson Imaging 2006, 23:339-344.
35. Pedrosa I., Sun M.R., Spencer M., et al. MR Imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics 2008, 28:985-1003.
36. Prasad S.R., Humphrey P.A., Catena J.R., et al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006, 26:1795-1810.
37. Quaia E., Bussani R., Cova M., et al. Radiologic-pathologic correlations of intratumoral tissue components in the most common solid and cystic renal tumors. Pictorial review. Eur Radiol 2005, 15(8):1734-1744.
38. Kim J.I., Cho J.Y., Moon K.C. Segmental enhancement inversion at biphasic multidetector CT: characteristic finding in small renal oncocytoma. Radiology 2009, 252(2):441-448.
39. Rosenkrantz A.B., Hindman N., Fitzgerald E.F., et al. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. AJR 2010, 195(6):W421-W427.
40. Griffin N., Grant L.A., Bharwani N., et al. Computed tomography in metastatic renal cell carcinoma. Semin Ultrasound CT MR 2009, 30(4):359-366.
41. Sheir K.Z., El-Azab M., Mosbah A., et al. Differentiation of renal cell carcinoma subtypes by multislice computerized tomography. J Urol 2005, 174(2):451-455.
42. Verine J., Pluvinage A., Bousquet G., et al. Hereditary renal cancer syndromes: an update of a systematic review. Eur Urol 2010, 58:701-710.
43. Robson C.J. Radical nephrectomy for renal cell carcinoma. J Urol 1963, 89:37-42.
44. Mueller-Lisse U.G., Mueller-Lisse U.L., Meindl T., et al. Staging of renal cell carcinoma. Eur Urol 2007, 17:2268-2277.
45. AJCC cancer staging handbook 2010, 553. Kidney, Springer, New York. 7th edition. S.B. Edge, D.R. Byrd, C.C. Compton (Eds.).
46. Novara G., Ficarra V., Antonelli A., et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?. Eur Urol 2010, 58:588-595.
47. Heuer R., Gill I.S., Guazzoni G., et al. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 2010, 57:223-232.
48. Tatli S., Acar M., Tuncali K., et al. Percutaneous cryoablation techniques and clinical applications. Diagn Interv Radiol 2010, 16:90-95.
49. Hines-Peralta A., Goldberg S.N. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 2004, 10:6328s-6334s.
50. Hinshaw J.L., Shadid A.M., Nakada S.Y., et al. Comparison of percutaneous and laparoscopic cryoablation for the treatment of solid renal masses. AJR 2008, 191:1159-1168.
51. Hui G.C., Tuncali K., Tatli S., et al. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 2008, 19(9):1311-1320.
52. Kawamoto S., Soloman S.B., Bluemke D.A., et al. Computed tomography and magnetic resonance imaging appearance of renal neoplasms after radiofrequency ablation and cryoablation. Semin Ultrasound CT MR 2009, 30:67-77.
53. Uppot R.N., Silverman S.G., Zagoria R.J., et al. Imaging-guided percutaneous ablation of renal cell carcinoma: a primer of how we do it. AJR 2009, 192:1558-1570.
54. Smith S., Gillams A. Imaging appearances following thermal ablation. Clin Radiol 2008, 63:1-11.
55. Tuncali K., vanSonnenberg E., Shankar S., et al. Evaluation of patients referred for percutaneous ablation of renal tumors: importance of a preprocedural diagnosis. AJR 2004, 183:575-582.
56. Remzi M., Marberger M. Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how?. Eur Urol 2009, 55:359-367.
57. Rabinovich R.A., Zelefsky M.J., Gaynor J.J., et al. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Onc 1994, 12(1):206-212.
58. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
59. Negrier S., Escudier B., Lasset C., et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998, 338:1272-1278.
60. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma. N Engl J Med 2003, 349:427-434.
61. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
62. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced renal cell carcinoma. N Engl J Med 2007, 356:125-134.
63. Motzer R.J., Michaelson M.D., Rosenberg J., et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007, 178:1883-1887.
64. Mickisch G.H.J., Garin A., van Poppel H., et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 2001, 358:966-970.
65. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
66. Choueiri T.K., Xie W., Kollmannsberger C., et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011, 185:60-66.
67. Breau R.H., Blute M.L. Surgery for renal cell carcinoma metastases. Curr Opin Urol 2010, 20(5):375-381.
68. Baccala A., Hedfepeth R., Kaouk J., et al. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007, 14:1095-1097.
69. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
70. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
71. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295(21):2516-2524.
72. Thiam R., Fournier L.S., Trinquart L., et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010, 21(5):936-941.
73. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007, 25:1760-1764.
74. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759.
75. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2010, 102:803-809.
76. Smith A.D., Leiber M.L., Shah S.N. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR 2010, 194:157-165.
77. Smith A.D., Shah S.N., Rini B.I., et al. Attenuation, size and structure (MASS) criteria; assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR 2010, 194:1470-1478.
78. Nathan P.D., Vinayan A., Stott D., et al. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010, 9(1):15-19.
79. Krajewski K.M., Guo M., Van den Abbeele A.D., et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011, 59(5):856-862.
80. Han K.S., Jung D.C., Choi J.F., et al. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 2010, 116(10):2332-2342.
81. Motzer R.J., Escudier B., Oudard S., et al. Phase 3 of everolimus for metastatic renal cell carcinoma. Cancer 2010, 116:4256-4265.
82. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
83. Cejka D., Kuntner C., Preusser M., et al. FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo. Br J Cancer 2009, 100:1739-1745.
84. Ma W.W., Jacene H., Song D., et al. [18F] Fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 2009, 27:2697-2704.
85. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182:396-403.
86. Palmowski M., Schifferdecker I., Zwick S., et al. Tumor perfusion assessed by dynamic contrast-enhanced MRI correlates to the grading of renal cell carcinoma: initial results. Eur J Radiol 2010, 74(3):e176-e180.
87. De Bazelaire C., Rofsky N.M., Duhamel G., et al. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma. Acad Radiol 2005, 12(3):347-357.
88. Gilad A.A., Israely T., Dafni H., et al. Functional and molecular mapping of uncoupling between vascular permeability and loss of vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in tumor angiogenesis. Int J Cancer 2005, 117(2):202-211.
89. Hahn O.M., Yang C., Medved M., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26(28):4572-4578.
90. Taouli B., Thakur R.K., Mannelli L., et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009, 251(2):398-407.
91. Lassau N., Chebil M., Chami L., et al. Dynamic contrast-enhanced ultrasonography: a new toll for the early evaluation of antiangiogenic treatment. Target Oncol 2010, 5:53-58.
92. Lamuraglia M., Escudier B., Chami L., et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006, 42:2472-2479.
93. Escudier B., Lassau N., Angevin E., et al. Phase I trial of sorafenib in combination with IFN alfa-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007, 13:1801-1809.
94. Lassau N., Koscielny S., Albiges L., et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 2010, 16(4):1216-1225.
95. Rosen M.A., Schnall M.D. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007, 13(2 pt 2):770s-776s.
96. Sheiman R.G., Sitek A. CT perfusion imaging: know its assumptions and limitations. Radiology 2008, 246(2):649. [author reply: 649-50].
97. Fournier L.S., Oudard S., Thiam R., et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010, 256:511-518.
98. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
99. Brasch R.C., Daldrup H., Shames D., et al. Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. Acad Radiol 1998, 5(Suppl 1):S2-S5.
100. Roberts T.P., Turetschek K., Preda A., et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 2002, 9(Suppl 2):S511-S513.
101. Jackson A., O'Connor J.P., Parker G.J., et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2009, 13:3449-3459.
102. Flaherty K.T., Rosen M.A., Heitjan D.F., et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008, 7:496-501.
103. Hahn O.M., Yang C., Medved M., et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafentib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-4578.
104. de Bazelaire C., Alsop D.C., George D., et al. MRI measured tumor blood flow change following antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008, 14:5548-5554.
105. Schor-Bardach R., Alsop D.C., Pedrosa I., et al. Does arterial spin labeling MRI measured tumor perfusion correlate with response of renal cell cancer to antiangiogenic therapy in a mouse model?. Radiology 2009, 51(3):731-742.
106. Rosenkrantz A.B., Niver B.E., Fitzgerald E.F., et al. Utility of the apparent diffusion coefficient for distinguishing clear cell renal cell carcinoma of low and high nuclear grade. AJR 2010, 195:W344-W351.
107. Katz-Brull R., Rofsky N.M., Morrin M.M., et al. Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 2005, 288:F637-F641.
108. Shreve P., Chiano P.C., Humes H.D., et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995, 36:1595-1601.
109. Maleddu A., Pantaleo M.A., Castellucci P., et al. 11C-Acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori 2009, 95:382-384.
110. Oyama N., Okazawa H., Kusukawa N., et al. 11C-acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 2009, 36:422-427.
111. Rosso L., Brock C.S., Gallo J.M., et al. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009, 69:120-127.
112. van der Veldt A.A., Luurtsema G., Lubberink M., et al. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumor resistance. Curr Pharm Des 2008, 14:2914-2931.
113. Nagengast W.B., De Vries E.G., Hospers G.A., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007, 48:1313-1319.
114. Nagengast W.B., De Korte M.A., Oude M., et al. 89Zr-Bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010, 51:761-767.
115. Divgi C., Pandit-Taskar N., Jungbluth A., et al. Preoperative characterization of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007, 8:304-310.
116. Divgi C. Molecular imaging for phenotypic characterization of urologic cancers: implication for management and targeted therapy (G250 PET). ASCO 2010 Genitourinary Cancers Symposium. San Francisco (CA), March 5-7, 2010.